SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-12-177943
Filing Date
2012-04-24
Accepted
2012-04-24 12:17:26
Documents
4
Period of Report
2011-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO.1 TO FORM 10-K d262321d10ka.htm 10-K/A 743568
2 CERTIFICATION BY SANJ K. PATEL AS CHIEF EXECUTIVE OFFICER. d262321dex311.htm EX-31.1 10031
3 CERTIFICATION BY CARSTEN BOESS AS CHIEF FINANCIAL OFFICER. d262321dex312.htm EX-31.2 10079
4 CERTIFICATION BY SANJ K. PATEL AS CEO AND CARSTEN BOESS AS CFO d262321dex321.htm EX-32.1 4395
  Complete submission text file 0001193125-12-177943.txt   769203
Mailing Address 128 SPRING STREET SUITE 520 LEXINGTON MA 02421
Business Address 128 SPRING STREET SUITE 520 LEXINGTON MA 02421 (781) 357-9900
SYNAGEVA BIOPHARMA CORP (Filer) CIK: 0000911326 (see all company filings)

IRS No.: 561808663 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 000-23155 | Film No.: 12775238
SIC: 2836 Biological Products, (No Diagnostic Substances)